title: Long-term Bladder and Upper Urinary Tract Follow-up Recurrence and Progression Rates of G1-2 Non-muscle-invasive Urothelial Carcinoma of the Bladder.
abstract: OBJECTIVE
  To evaluate the risk of long-term tumor recurrence and progression in patients with low- and intermediate-risk non-muscle-invasive bladder cancers, which could facilitate optimization in the follow-up schedules.
  
  
  METHODS
  A single-institution, retrospective analysis of 704 patients with primary TaG1, TaG2, T1G1, and T1G2 urothelial carcinomas of the bladder without concomitant carcinoma in situ, treated with transurethral resection, was performed. Response was determined and monitored by routine periodic urine cytology, cystoscopy, and upper tract imaging.
  
  
  RESULTS
  The median follow-up was 64.9 months (maximum, 120 months). Among all of the tumors, 59.3% did not relapse, 36.6% recurred in the bladder during the first 5 years of surveillance, and only 3.6% recurred after 5 years of follow-up. Eight urothelial bladder cancers (1.1%) progressed in stage, and 87.5% of the progressions occurred during the first 5 years of surveillance. An upper urinary tract recurrence was detected in 2.4% of the patients; 94.1% were diagnosed within the upper urinary tract during the first 5 years of follow-up and 5.9% occurred after 5 years of surveillance.
  
  
  CONCLUSIONS
  G1-2 urothelial bladder cancers recur and progress uncommonly in the long-term period. Although limited by its retrospective nature, the present study provides potential grounds for re-examination of the follow-up schedule for patients with primary non-muscle-invasive bladder cancer G1-2 tumors who remain asymptomatic and disease-free for at least 5 years.
authors.affiliation: Servicio de Urología, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Thomas
authors.initials: T
authors.lastname: Golabesk
authors.affiliation: Servicio de Urología, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: jpalou@fundacio-puigvert.es.
authors.forename: Joan
authors.initials: J
authors.lastname: Palou
authors.affiliation: Servicio de Urología, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Oscar
authors.initials: O
authors.lastname: Rodriguez
authors.affiliation: Servicio de Urología, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Ruben
authors.initials: R
authors.lastname: Parada
authors.affiliation: Servicio de Urología, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Sergio
authors.initials: S
authors.lastname: Skrobot
authors.affiliation: Servicio de Urología, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Peña
authors.affiliation: Servicio de Urología, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Humberto
authors.initials: H
authors.lastname: Villavicencio
mesh_terms: D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D019459:Urothelium